|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fushida S, Kinoshita J, Yagi Y, Funaki H,
Kinami S, Ninomiya I, Fujimura T, Nishimura G, Kayahara M and Ohta
T: Dual anti-cancer effects of weekly intraperitoneal docetaxel in
treatment of advanced gastric cancer patients with peritoneal
carcinomatosis: A feasibility and pharmacokinetic study. Oncol Rep.
19:1305–1310. 2008.PubMed/NCBI
|
|
3
|
Fushida S, Kinoshita J, Kaji M, Hirono Y,
Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y and Fujimura T; Society
for Study of Peritoneal Carcinomatosis in Gastric Cancer, : Phase
I/II study of intraperitoneal docetaxel plus S-1 for the gastric
cancer patients with peritoneal carcinomatosis. Cancer Chemother
Pharmacol. 71:1265–1272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsukada T, Fushida S, Harada S, Yagi Y,
Kinoshita J, Oyama K, Tajima H, Fujita H, Ninomiya I, Fujimura T
and Ohta T: The role of human peritoneal mesothelial cells in the
fibrosis and progression of gastric cancer. Int J Oncol.
41:476–482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamaguchi T, Fushida S, Yamamoto Y,
Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I,
Munesue S, et al: Tumor-associated macrophages of the M2 phenotype
contribute to progression in gastric cancer with peritoneal
dissemination. Gastric Cancer. 19:1052–1065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lal I, Dittus K and Holmes CE: Platelets,
coagulation and fibrinolysis in breast cancer progression. Breast
Cancer Res. 15:2072013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takagi S, Takemoto A, Takami M, Oh-Hara T
and Fujita N: Platelets promote osteosarcoma cell growth through
activation of the platelet-derived growth factor receptor-Akt
signaling axis. Cancer Sci. 105:983–988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bambace NM and Holmes CE: The platelet
contribution to cancer progression. J Thromb Haemost. 9:237–249.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ludwig RJ, Boehme B, Podda M, Henschler R,
jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R and Gille J:
Endothelial P-selectin as a target of heparin action in
experimental melanoma lung metastasis. Cancer Res. 64:2743–2750.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ihsikawa S, Miyashita T, Inokuchi M,
Hayashi H, Oyama K, Tajima H, Takamura H, Ninomiya I, Ahmed AK,
Harman JW, et al: Platelets surrounding primary tumor cells are
related to chemoresistance. Oncol Rep. 36:787–794. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Saito H, Fushida S, Miyashita T, Oyama K,
Yamaguchi T, Tsukada T, Kinoshita J, Tajima H, Ninomiya I and Ohta
T: Potential of extravasated platelet aggregation as a surrogate
marker for overall survival in patients with advanced gastric
cancer treated with preoperative docetaxel, cisplatin and S-1: A
retrospective observational study. BMC Cancer. 17:2942017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Assoian RK, Komoriya A, Meyers CA, Miller
DM and Sporn MB: Transforming growth factor-beta in human
platelets. Identification of a major storage site, purification,
and characterization. J Biol Chem. 258:7155–7160. 1983.PubMed/NCBI
|
|
13
|
Labelle M, Begum S and Hynes RO: Direct
signaling between platelets and cancer cells induces an
epithelial-mesenchymal-like transition and promotes metastasis.
Cancer Cell. 20:576–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu H, Zhang T, Ye J, Li H, Huang J, Li X,
Wu B, Huang X and Hou J: Tumor-infiltrating lymphocytes predict
response to chemotherapy in patients with advance non-small cell
lung cancer. Cancer Immunol Immunother. 61:1849–1856. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishikawa H and Sakaguchi S: Regulatory T
cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI
|
|
16
|
Winkler I, Wilczynska B, Bojarska-Junak A,
Gogacz M, Adamiak A, Postawski K, Darmochwal-Kolarz D, Rechberger T
and Tabarkiewicz J: Regulatory T lymphocytes and transforming
growth factor beta in epithelial ovarian tumors-prognostic
significance. J Ovarian Res. 8:392015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kusmartsev S and Gabrilovich DI: Role of
immature myeloid cells in mechanisms of immune evasion in cancer.
Cancer Immunol Immunother. 55:237–245. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Talmadge JE: Pathways mediating the
expansion and immunosuppressive activity of myeloid-derived
suppressor cells and their relevance to cancer therapy. Clin Cancer
Res. 13(18 Pt 1):5243–5248. 2007. View Article : Google Scholar
|
|
19
|
World Health Organization, .
Classification of tumours. 1:(5). World Health Organization.
(Geneva). 54–64. 2019.
|
|
20
|
Xu XR, Carrim N, Neves MA, McKeown T,
Stratton TW, Coelho RM, Lei X, Chen P, Xu J, Dai X, et al:
Platelets and platelet adhesion molecules: Novel mechanisms of
thrombosis and anti-thrombotic therapies. Thromb J. 14 (Suppl
1):S292016. View Article : Google Scholar
|
|
21
|
Keck B, Wach S, Goebell PJ, Kunath F,
Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B and Hartmann A:
SNAI1 protein expression is an independent negative prognosticator
in muscle-invasive bladder cancer. Ann Surg Oncol. 20:3669–3674.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oda N, Shimazu K, Naoi Y, Morimoto K,
Shimomura A, Shimoda M, Kagara N, Maruyama N, Kim SJ and Noguchi S:
Intratumoral regulatory T cells as an independent predictive factor
for pathological complete response to neoadjuvant paclitaxel
followed by 5-FU/epirubicin/cyclophosphamide in breast cancer
patients. Breast Cancer Res Treat. 136:107–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong J, Li J, Liu SM, Feng XY, Chen S,
Chen YB and Zhang XS: CD33+/p-STAT1+ double-positive cell as a
prognostic factor for stage IIIa gastric cancer. Med Oncol.
30:4422013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mikami J, Kurokawa Y, Takahashi T,
Miyazaki Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M
and Doki Y: Antitumor effect of antiplatelet agents in gastric
cancer cells: An in vivo and in vitro study. Gastric Cancer.
19:817–826. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stegner D, Dutting S and Nieswandt M:
Mechanistic explanation for platelet contribution to cancer
metastasis. Thromb Res. 133 (Suppl 2):S149–S157. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han H, Cao FL, Wang BZ, Mu XR, Li GY and
Wang XW: Expression of angiogenesis regulatory proteins and
epithelial-mesenchymal transition factors in platelets of the
breast cancer patients. ScientificWorldJournal. 2014:8782092014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong HN, Won YJ, Shim JH, Kim HJ, Han SH,
Kim BS and Kim HS: Cancer-associated fibroblasts promote gastric
tumorigenesis through EphA2 activation in a ligand-independent
manner. J Cancer Res Clin Oncol. 144:1649–1663. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun L, Wang Q, Chen B, Zhao Y, Shen B,
Wang X, Zhu M, Li Z, Zhao X, Xu C, et al: Human gastric cancer
mesenchymal stem cell-derived IL15 contributes to tumor cell
epithelial-mesenchymal transition via upregulation tregs ratio and
PD-1 expression in CD4+T cell. Stem Cells Dev.
27:1203–1214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan Y, Zhang J, Li JH, Liu X, Wang JZ, Qu
HY, Wang JS and Duan XY: High tumor-associated macrophages
infiltration is associated with poor prognosis and may contribute
to the phenomenon of epithelial-mesenchymal transition in gastric
cancer. Onco Targets Ther. 9:3975–3983. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yu J, Wang Y, Yan F, Zhang P, Li H, Zhao
H, Yan C, Yan F and Ren X: Noncanonical NF-kB activation mediates
stat3-stimulated IDO upregulation in myeloid-derived suppressor
cells in breast cancer. J immunol. 193:2574–2586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gabrilovich D, Ishida T, Oyama T, Ran S,
Kravtsov V, Nadaf S and Carbone DP: Vascular endothelial growth
factor inhibits the development of dendritic cells and dramatically
affects the differentiation of multiple hematopoietic lineages in
vivo. Blood. 92:4150–4166. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang L and Moses HL: Transforming growth
factor beta: Tumor suppressor or promoter? Are host immune cells
the answer? Cancer Res. 68:9107–9111. 2008.PubMed/NCBI
|
|
33
|
Melani C, Sangaletti S, Barazzetta FM,
Werb Z and Colombo MP: Amino-bisphosphonate-mediated MMP-9
inhibition breaks the tumor-bone marrow axis responsible for
myeloid-derived suppressor cell expansion and macrophage
infiltration in tumor stroma. Cancer Res. 67:11438–11446. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fushida S, Oyama K, Kinoshita J, Yagi Y,
Okamoto K, Tajima H, Ninomiya I, Fujimura T and Ohta T: VEGF is a
target molecule for peritoneal metastasis and malignant ascites in
gastric cancer: Prognostic significance of VEGF in ascites and
efficacy of anti-VEGF monoclonal antibody. Onco Targets Ther.
6:1445–1451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Voron T, Marcheteau E, Pernot S, Colussi
O, Tartour E, Taieb J and Terme M: Control of the immune response
by pro-angiogenic factors. Front Oncol. 4:702014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Horikawa N, Abiko K, Matsumura N,
Hamanishi J, Baba T, Yamaguchi K, Yoshioka Y, Koshiyama M and
Konishi I: Expression of vascular endothelial growth factor in
ovarian cancer inhibits tumor immunity through the accumulation of
myeloid-derived suppressor cells. Clin Cancer Res. 23:587–599.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang J, Yan J and Liu B: Targeting
VEGF/VEGFR to modulate antitumor immunity. Front Immunol.
9:9782018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Secondini C, Coquoz O, Spagnuolo L,
Spinetti T, Peyvandi S, Ciarloni L, Botta F, Bourquin C and Rüegg
C: Arginase inhibition suppresses lung metastasis in the 4T1 breast
cancer model independently of the immunomodulatory and
anti-metastatic effects of VEGFR-2 blockade. Oncoimmunology.
6:e13164372017. View Article : Google Scholar : PubMed/NCBI
|
